Praxis Precision Medicines Reports Q4 2025 Financials and Strategic Developments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2026
0mins
Should l Buy PRAX?
Source: Yahoo Finance
- Rising Operating Expenses: Praxis Precision Medicines reported operating expenses of $97 million in Q4 2025, a significant increase from $71.4 million in Q4 2024, primarily driven by higher R&D and G&A costs, which may impact profitability in the short term.
- Strong Cash Reserves: As of the end of Q4 2025, Praxis had $926 million in cash and equivalents, with projections indicating that post-January 2026 offering, total cash could reach approximately $1.5 billion, providing a robust financial foundation for future operations and growth.
- Significant Clinical Advancements: The company achieved multiple clinical and regulatory milestones in 2025, including breakthrough designation for elixacalmide, which is expected to offer a novel treatment for essential tremor, with market opportunities exceeding $20 billion.
- Market Preparation Efforts: Praxis is preparing for the commercial launch of elixacalmide by implementing a comprehensive medical education campaign and making key hires to ensure a smooth market entry and enhance disease awareness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRAX
Wall Street analysts forecast PRAX stock price to rise
15 Analyst Rating
14 Buy
0 Hold
1 Sell
Strong Buy
Current: 318.220
Low
95.00
Averages
456.71
High
843.00
Current: 318.220
Low
95.00
Averages
456.71
High
843.00
About PRAX
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Praxis Grants Restricted Stock Units to New Employees
- Employee Incentive Program: On March 2, 2026, Praxis Precision Medicines granted 2,931 restricted stock units to fourteen new non-executive employees, aimed at attracting top talent in compliance with Nasdaq Listing Rule 5635(c)(4).
- Stock Unit Vesting Schedule: The restricted stock units will vest in four equal annual installments, contingent upon the employees' continued employment, thereby aligning employee interests with the company's long-term goals and enhancing retention rates.
- Strategic Talent Acquisition: This grant is part of the 2024 Inducement Plan, specifically designed to attract individuals who were not previously employed by the company, highlighting Praxis's commitment to talent acquisition and its competitive edge in the biopharmaceutical industry.
- Company Overview: Praxis is a leading CNS precision neuroscience biopharmaceutical company focused on translating insights from genetic epilepsies into therapies for CNS disorders, boasting multiple late-stage product candidates that demonstrate strong R&D capabilities and market potential.
See More
Baker Bros. Increases Praxis Stake to 1.94% with $81.38M Purchase
- Stake Increase: Baker Bros. Advisors increased its stake in Praxis Precision Medicines by 437,000 shares during Q4 2025, valued at $81.38 million, indicating strong confidence in the company's future prospects.
- Market Valuation Growth: The post-trade valuation of Praxis increased by $295.48 million due to trading activity and price movements, reflecting positive market sentiment towards its clinical-stage therapies.
- R&D Investment: In 2025, Praxis reported R&D expenses of $267.1 million, with a net loss of $303.3 million, yet the company remains committed to advancing its treatments for central nervous system disorders.
- Cash Flow Position: As of the end of 2025, Praxis had $926.1 million in cash and investments, with an additional $621 million from a January 2026 offering expected to fund operations into 2028, demonstrating financial stability.
See More
Baker Bros. Advisors Increases Stake in Praxis Precision Medicines
- Share Acquisition: Baker Bros. Advisors LP increased its stake in Praxis Precision Medicines by 437,000 shares in Q4 2025, with an estimated transaction value of $81.38 million, indicating strong confidence in the company's future prospects.
- Market Value Increase: Following the acquisition, Baker Bros. now holds 1,126,488 shares, with the quarter-end position value rising by $295.48 million, reflecting both stock price appreciation and active trading dynamics.
- Strong Financial Position: Praxis Precision Medicines ended 2025 with $926.1 million in cash and investments, and an additional $621 million from a January 2026 offering is expected to fund operations through 2028, showcasing a robust financial foundation.
- R&D Investment: The company reported $267.1 million in R&D expenses for 2025, with a full-year net loss of $303.3 million; however, its strategic focus on CNS therapeutics continues to attract investor interest due to significant revenue potential.
See More
Perceptive Advisors Increases Stake in Praxis Precision Medicines
- Stake Increase: Perceptive Advisors increased its stake in Praxis Precision Medicines by 431,432 shares during Q4 2025, with an estimated transaction value of $80.34 million, reflecting strong confidence in the company's future prospects.
- Market Value Growth: Following this purchase, Praxis's quarter-end market value increased by $505.38 million, indicating a dual impact from both the share purchase and subsequent stock price appreciation, showcasing market recognition of its clinical pipeline.
- Financial Position: As of February 17, 2026, Praxis shares were priced at $328.04, up 320% year-over-year, while the company reported $926 million in cash and investments, providing ample financial support for future commercialization efforts.
- R&D Investment: In 2025, Praxis's research and development spending reached $267 million, indicating a significant investment in multiple programs aimed at accelerating the development of its clinical-stage drug candidates.
See More
Perceptive Advisors Acquires 431,432 Shares of Praxis Precision Medicines
- Share Acquisition Details: Perceptive Advisors increased its stake in Praxis Precision Medicines by 431,432 shares during Q4 2025, with an estimated transaction value of $80.34 million, reflecting strong confidence in the company's future prospects.
- Position Value Growth: Following this acquisition, the value of Praxis's holdings reached $588.30 million, an increase of $505.38 million from the previous quarter-end, indicating significant stock price appreciation and positive investor sentiment.
- Financial Overview: As of February 17, 2026, Praxis shares were priced at $328.04, up 320% year-over-year, despite a net loss of $273.04 million in 2025, suggesting market optimism regarding its future product pipeline.
- R&D and Market Outlook: Praxis has submitted two NDAs to the FDA and is actively preparing for commercialization, with multiple clinical trial results expected in 2026, which could further enhance its market position in the central nervous system sector.
See More
Perceptive Advisors Increases Stake in Celcuity
- Stake Increase: Perceptive Advisors purchased an additional 203,881 shares of Celcuity in Q4 2026, with an estimated transaction value of $16.76 million, indicating strong confidence in the company's future growth potential.
- Ownership Proportion Rise: Following this purchase, Perceptive Advisors' stake in Celcuity increased to 5.62%, highlighting its significance within the investment portfolio and further drawing market attention to Celcuity.
- Market Performance: As of February 17, 2026, Celcuity shares were priced at $107.32, reflecting a staggering 700% increase over the past year, underscoring strong market anticipation for its drug development.
- FDA Review Progress: Celcuity's new drug application for gedatolisib has received Priority Review from the FDA, with a decision expected by July 17, 2026, a critical timeline that could significantly impact its future market performance.
See More
Praxis Grants Restricted Stock Units to New Employees
- Employee Incentive Program: On March 2, 2026, Praxis Precision Medicines granted 2,931 restricted stock units to fourteen new non-executive employees, aimed at attracting top talent in compliance with Nasdaq Listing Rule 5635(c)(4).
- Stock Unit Vesting Schedule: The restricted stock units will vest in four equal annual installments, contingent upon the employees' continued employment, thereby aligning employee interests with the company's long-term goals and enhancing retention rates.
- Strategic Talent Acquisition: This grant is part of the 2024 Inducement Plan, specifically designed to attract individuals who were not previously employed by the company, highlighting Praxis's commitment to talent acquisition and its competitive edge in the biopharmaceutical industry.
- Company Overview: Praxis is a leading CNS precision neuroscience biopharmaceutical company focused on translating insights from genetic epilepsies into therapies for CNS disorders, boasting multiple late-stage product candidates that demonstrate strong R&D capabilities and market potential.
See More
Baker Bros. Increases Praxis Stake to 1.94% with $81.38M Purchase
- Stake Increase: Baker Bros. Advisors increased its stake in Praxis Precision Medicines by 437,000 shares during Q4 2025, valued at $81.38 million, indicating strong confidence in the company's future prospects.
- Market Valuation Growth: The post-trade valuation of Praxis increased by $295.48 million due to trading activity and price movements, reflecting positive market sentiment towards its clinical-stage therapies.
- R&D Investment: In 2025, Praxis reported R&D expenses of $267.1 million, with a net loss of $303.3 million, yet the company remains committed to advancing its treatments for central nervous system disorders.
- Cash Flow Position: As of the end of 2025, Praxis had $926.1 million in cash and investments, with an additional $621 million from a January 2026 offering expected to fund operations into 2028, demonstrating financial stability.
See More
Baker Bros. Advisors Increases Stake in Praxis Precision Medicines
- Share Acquisition: Baker Bros. Advisors LP increased its stake in Praxis Precision Medicines by 437,000 shares in Q4 2025, with an estimated transaction value of $81.38 million, indicating strong confidence in the company's future prospects.
- Market Value Increase: Following the acquisition, Baker Bros. now holds 1,126,488 shares, with the quarter-end position value rising by $295.48 million, reflecting both stock price appreciation and active trading dynamics.
- Strong Financial Position: Praxis Precision Medicines ended 2025 with $926.1 million in cash and investments, and an additional $621 million from a January 2026 offering is expected to fund operations through 2028, showcasing a robust financial foundation.
- R&D Investment: The company reported $267.1 million in R&D expenses for 2025, with a full-year net loss of $303.3 million; however, its strategic focus on CNS therapeutics continues to attract investor interest due to significant revenue potential.
See More
Perceptive Advisors Increases Stake in Praxis Precision Medicines
- Stake Increase: Perceptive Advisors increased its stake in Praxis Precision Medicines by 431,432 shares during Q4 2025, with an estimated transaction value of $80.34 million, reflecting strong confidence in the company's future prospects.
- Market Value Growth: Following this purchase, Praxis's quarter-end market value increased by $505.38 million, indicating a dual impact from both the share purchase and subsequent stock price appreciation, showcasing market recognition of its clinical pipeline.
- Financial Position: As of February 17, 2026, Praxis shares were priced at $328.04, up 320% year-over-year, while the company reported $926 million in cash and investments, providing ample financial support for future commercialization efforts.
- R&D Investment: In 2025, Praxis's research and development spending reached $267 million, indicating a significant investment in multiple programs aimed at accelerating the development of its clinical-stage drug candidates.
See More
Perceptive Advisors Acquires 431,432 Shares of Praxis Precision Medicines
- Share Acquisition Details: Perceptive Advisors increased its stake in Praxis Precision Medicines by 431,432 shares during Q4 2025, with an estimated transaction value of $80.34 million, reflecting strong confidence in the company's future prospects.
- Position Value Growth: Following this acquisition, the value of Praxis's holdings reached $588.30 million, an increase of $505.38 million from the previous quarter-end, indicating significant stock price appreciation and positive investor sentiment.
- Financial Overview: As of February 17, 2026, Praxis shares were priced at $328.04, up 320% year-over-year, despite a net loss of $273.04 million in 2025, suggesting market optimism regarding its future product pipeline.
- R&D and Market Outlook: Praxis has submitted two NDAs to the FDA and is actively preparing for commercialization, with multiple clinical trial results expected in 2026, which could further enhance its market position in the central nervous system sector.
See More
Perceptive Advisors Increases Stake in Celcuity
- Stake Increase: Perceptive Advisors purchased an additional 203,881 shares of Celcuity in Q4 2026, with an estimated transaction value of $16.76 million, indicating strong confidence in the company's future growth potential.
- Ownership Proportion Rise: Following this purchase, Perceptive Advisors' stake in Celcuity increased to 5.62%, highlighting its significance within the investment portfolio and further drawing market attention to Celcuity.
- Market Performance: As of February 17, 2026, Celcuity shares were priced at $107.32, reflecting a staggering 700% increase over the past year, underscoring strong market anticipation for its drug development.
- FDA Review Progress: Celcuity's new drug application for gedatolisib has received Priority Review from the FDA, with a decision expected by July 17, 2026, a critical timeline that could significantly impact its future market performance.
See More
